|
|
| | Myo-Inositol Trispyrophosphate HexasodiuM Salt Basic information |
| Product Name: | Myo-Inositol Trispyrophosphate HexasodiuM Salt | | Synonyms: | Myo-Inositol Cyclic 1,2:3,4:5,6-Tris(dihydrogen pyrophosphate)) HexasodiuM Salt;Myo-Inositol Cyclic 1,2:3,4:5,6-Tris(P,P'-dihydrogen diphosphate) HexasodiuM Salt;Myo-Inositol Tripyrphosphate HexasodiuM salt;Myo-Inositol Trispyrophosphate HexasodiuM Salt 9;Myo-Inositol Trispyrophosphate HexasodiuM Salt;ITTP HexasodiuM Salt;Inositol cyclic-1,2:3,4:5,6-tris(P,P'-dihydrogen diphosphate) hexasodium salt;MYO-INOSITOL TRISPYROPHOSPHATE HEXASODIUM (ITPP) | | CAS: | 23103-35-7 | | MF: | C6H13NaO21P6 | | MW: | 629.98 | | EINECS: | | | Product Categories: | Phosphorylating and Phosphitylating Agents;Inositols;Intermediates & Fine Chemicals;Pharmaceuticals | | Mol File: | 23103-35-7.mol |  |
| | Myo-Inositol Trispyrophosphate HexasodiuM Salt Chemical Properties |
| Melting point | >270°C (dec.) | | storage temp. | Hygroscopic, -20°C Freezer, Under Inert Atmosphere | | solubility | Water (Slightly, Sonicated) | | form | Solid | | color | White to Off-White | | Stability: | Hygroscopic |
| | Myo-Inositol Trispyrophosphate HexasodiuM Salt Usage And Synthesis |
| Chemical Properties | Off-White Solid | | Uses | A novel membrane-permeant allosteric effector of hemoglobin (Hb), enhances the regulated oxygen release capacity of red blood cells, thus counteracting the effects of hypoxia in diseases such as cancer and cardiovascular ailments. | | in vivo | Non-salt dose:
myo-Inositol trispyrophosphate (1.5 g/kg; intraperitoneal injection; twice a week for 4 weeks) has a protective effect in rat model of myocardial infarction[1].
myo-Inositol trispyrophosphate (1.5 g/kg; intravenous injection; once a week for 11 weeks) has antitumor activity in a rat model of pancreatic cancer[2]. | Animal Model: | Male Wistar rats (280-320 g) with myocardial infarction[1] | | Dosage: | 1.5 g/kg (Non-salt dose) | | Administration: | Intraperitoneal injection (i.p.); twice a week for 4 weeks | | Result: | Essentially halted the increase of LV dilation and significantly reduced impairment of LV ejection fraction, while it had no effect on sham-operated rats.
|
| Animal Model: | DSL-6A/C1 tumors treated immunocompetent male Lewis rats[2] | | Dosage: | 1.5 g/kg (Non-salt dose) | | Administration: | Intravenous injection (i.v.); once a week for 11 weeks | | Result: | Significantly extended the survival time of rats.
Basically did not cause liver metastasis and primary tumor growth was restricted to 2 cm3.
Restored the pO2 pressure in tumors reducing hypoxia-inducible and proangiogenic factors. |
|
| | Myo-Inositol Trispyrophosphate HexasodiuM Salt Preparation Products And Raw materials |
|